VERA250117P45000
- 2.40
- 0.000.00%
Vera Therapeutics Newsroom
TD Cowen Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $60
Vera Therapeutics (VERA) Receives a Buy From TD Cowen
Vera Therapeutics (VERA) Gets a Buy From J.P. Morgan
Wells Fargo Initiates Vera Therapeutics(VERA.US) With Buy Rating, Announces Target Price $70
Vera Therapeutics Price Target Raised to $38.00/Share From $30.00 by Wedbush
Vera Therapeutics Is Maintained at Neutral by Wedbush
Vera Therapeutics Analyst Ratings
Evercore Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $75
TD Cowen Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $60
TD Cowen Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $60
LifeSci Capital Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $70
Vera Therapeutics: Strong Buy Rating Backed by Financial Stability and Promising Atacicept Data
Vera Therapeutics Analyst Ratings
J.P. Morgan Maintains Vera Therapeutics(VERA.US) With Buy Rating, Raises Target Price to $75
LifeSci Capital Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $70
Vera Therapeutics Analyst Ratings
Guggenheim Maintains Vera Therapeutics(VERA.US) With Buy Rating, Raises Target Price to $64
Evercore Maintains Vera Therapeutics(VERA.US) With Buy Rating, Raises Target Price to $75
A Quick Look at Today's Ratings for Vera Therapeutics(VERA.US), With a Forecast Between $60 to $75
Promising Clinical Data and Strong Financials Justify Buy Rating for Vera Therapeutics Amid Atacicept's Potential in IgAN